Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered

Cardiol J. 2021;28(5):798-799. doi: 10.5603/CJ.a2021.0078. Epub 2021 Jul 9.

Authors

Filippo Sanfilippo¹, Luigi La Via², Federica Merola², Marinella Astuto²

Affiliations

¹ Department of Anesthesia and Intensive Care, A.O.U. Policlinico-San Marco, Catania, Catania, Italy. filipposanfi@yahoo.it.
² Department of Anesthesia and Intensive Care, A.O.U. Policlinico-San Marco, Catania, Catania, Italy.

No abstract available

Publication types

Letter
Comment

MeSH terms

Heart Failure* / diagnosis
Heart Failure* / drug therapy
Humans
Hydrazones / therapeutic use
Pyridazines*
Simendan

Substances

Hydrazones
Pyridazines
Simendan